BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sakaida I, Terai S, Kurosaki M, Okada M, Hirano T, Fukuta Y. Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study). J Gastroenterol 2020;55:800-10. [PMID: 32388692 DOI: 10.1007/s00535-020-01691-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Singh S, Roy A. Tolvaptan for difficult- to -treat ascites: Difficulties in opening doors for GWAS application. Liver Int 2021;41:3033. [PMID: 34486803 DOI: 10.1111/liv.15045] [Reference Citation Analysis]
2 Adachi T, Takaki A, Sato S, Tobita H, Kobashi H, Kinomura M, Nakatsuka A, Oyama A, Wada N, Sakata M, Takeuchi Y, Yasunaka T, Onishi H, Shiraha H, Okada H. High expression of a vascular stricture-related marker is predictive of an early response to tolvaptan, and a low fractional excretion of sodium is predictive of a poor long-term survival after tolvaptan administration for liver cirrhosis. Hepatol Res 2020;50:1347-54. [PMID: 32939957 DOI: 10.1111/hepr.13573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Yatsuhashi H, Sano H, Hirano T, Shibasaki Y. Real-world hospital mortality of liver cirrhosis inpatients in Japan: a large-scale cohort study using a medical claims database: Prognosis of liver cirrhosis. Hepatol Res 2021;51:682-93. [PMID: 33710718 DOI: 10.1111/hepr.13635] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Shigefuku R, Iwasa M, Eguchi A, Tempaku M, Tamai Y, Suzuki T, Takei Y. Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites. Intern Med 2021;60:3359-68. [PMID: 34719623 DOI: 10.2169/internalmedicine.7291-21] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Hiramine Y, Uto H, Mawatari S, Kanmura S, Imamura Y, Hiwaki T, Saishoji A, Oku M, Tokushige K, Maenohara S, Ido A. Impact of acute kidney injury on prognosis and the effect of tolvaptan in patients with hepatic ascites. J Gastroenterol 2021;56:54-66. [PMID: 32959093 DOI: 10.1007/s00535-020-01727-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Hosui A, Tanimoto T, Okahara T, Ashida M, Ohnishi K, Wakahara Y, Kusumoto Y, Yamaguchi T, Sueyoshi Y, Hirao M, Yamada T, Hiramatsu N. Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites. J Clin Med 2021;10:294. [PMID: 33466878 DOI: 10.3390/jcm10020294] [Reference Citation Analysis]
7 Adachi T, Takeuchi Y, Takaki A, Oyama A, Wada N, Onishi H, Shiraha H, Okada H. Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan. Int J Mol Sci 2021;22:5582. [PMID: 34070416 DOI: 10.3390/ijms22115582] [Reference Citation Analysis]
8 Nakai M, Suda G, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, Shigesawa T, Suzuki K, Nakamura A, Kawagishi N, Ohara M, Umemura M, Sho T, Morikawa K, Ogawa K, Sakamoto N. Durable response without recurrence to Tolvaptan improves long-term survival. J Gastroenterol 2020;55:1150-61. [PMID: 32851487 DOI: 10.1007/s00535-020-01721-8] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Tang J, Wang Y, Han T, Mao Q, Cheng J, Ding H, Shang J, Zhang Q, Niu J, Ji F, Chen C, Jia J, Jiang X, Lv N, Gao Y, Wang Z, Wei Z, Chen Y, Zeng M, Mao Y. Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial. BMC Gastroenterol 2020;20:391. [PMID: 33213378 DOI: 10.1186/s12876-020-01536-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]